<DOC>
	<DOCNO>NCT02012140</DOCNO>
	<brief_summary>Ticagrelor therapy show reduce rate cardiovascular event all-cause mortality compare clopidogrel therapy patient acute coronary syndrome ( ACS ) . The benefit study would demonstrate ticagrelor therapy associate equivalent platelet inhibition irrespective disease status patient undergo PCI .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Ticagrelor Patients With Stable Angina , NSTEMI STEMI Undergoing PCI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Stable Angina : Stable coronary artery disease patient document ischemia undergoing elective PCI enrolled.Inclusion criterion enrollment ACS group without STsegment elevation , require onset symptom previous 48 hour . NSTEMI For patient ACS without STsegment elevation ( NTSEMI ) , two follow criterion meet : positive test biomarker ( troponin I ) accordance universal definition indicate myocardial necrosis STsegment change electrocardiography , indicate ischemia meet criterion STEMI . STEMI For patient ACS STsegment elevation , follow two inclusion criterion meet : either persistent STsegment elevation least 0.1 mV least two contiguous lead new left bundlebranch block ; intention perform primary PCI 24 hour symptom onset Patients P2Y12 receptor blocker , oral anticoagulant , GPIIb/IIIa receptor blocker therapy . Presence history follow : ischemic hemorrhagic stroke ; transient ischemic attack ( TIA ) ; intracranial neoplasm ; arteriovenous malformation , aneurysm ; intracranial hemorrhage ; head trauma ( within 3 month study entry ) History refractory ventricular arrhythmia increase risk bradycardic event ( eg , subject without pacemaker sick sinus syndrome , 2nd 3rd degree atrioventricular ( AV ) block bradycardicrelated syncope ) History evidence congestive heart failure ( New York Heart Association Class III â‰¤ 6 month screen Severe hepatic impairment define ALT &gt; 2.5 X ULN Uncontrolled hypertension , systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg screen Severely impaired renal function ( glomerular filtration rate &lt; 30 mL/minute ) dialysis Platelet count &lt; 100 X103 , illicit drug alcohol abuse , prothrombin time &gt; 1.5 time control , haematocrit &lt; 30 % , creatinine &gt; 2.0 mg/dl . Contraindication reason ticagrelor administer ( eg , hypersensitivity , active bleeding , moderate severe liver disease , history previous intracranial bleed , GI bleed within past 6 month , major surgery within 30 day ) Fibrinolytic therapy 24 hour prior PCI , plan fibrinolytic treatment follow PCI . Participation another investigational drug device study last 30 Pregnancy lactation Concomitant oral intravenous therapy ( see example ) strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer stop course study Strong inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atanazavir Substrates narrow therapeutic index : cyclosporine , quinidine Strong inducer : rifampin/rifampicin , phenytoin , carbamazepine Any condition opinion investigator , may either put patient risk influence result study ( eg , cardiogenic shock severe haemodynamic instability , active cancer , risk noncompliance , risk lose follow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>